BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36825600)

  • 1. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1.
    Xia R; Hu C; Ye Y; Zhang X; Li T; He R; Zheng S; Wen X; Chen R
    Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36825600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
    Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
    EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair.
    Zhang X; Zheng S; Hu C; Li G; Lin H; Xia R; Ye Y; He R; Li Z; Lin Q; Chen R; Zhou Q
    Oncogene; 2022 Apr; 41(16):2372-2389. PubMed ID: 35264742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
    Kalisz M; Bernardo E; Beucher A; Maestro MA; Del Pozo N; Millán I; Haeberle L; Schlensog M; Safi SA; Knoefel WT; Grau V; de Vas M; Shpargel KB; Vaquero E; Magnuson T; Ortega S; Esposito I; Real FX; Ferrer J
    EMBO J; 2020 May; 39(9):e102808. PubMed ID: 32154941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer.
    Zheng S; Tian Q; Yuan Y; Sun S; Li T; Xia R; He R; Luo Y; Lin Q; Fu Z; Zhou Y; Chen R; Hu C
    J Exp Clin Cancer Res; 2023 Nov; 42(1):324. PubMed ID: 38012734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A.
    Hoskins JW; Jia J; Flandez M; Parikh H; Xiao W; Collins I; Emmanuel MA; Ibrahim A; Powell J; Zhang L; Malats N; Bamlet WR; Petersen GM; Real FX; Amundadottir LT
    Carcinogenesis; 2014 Dec; 35(12):2670-8. PubMed ID: 25233928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte nuclear factor 1A (HNF1A) as a possible tumor suppressor in pancreatic cancer.
    Luo Z; Li Y; Wang H; Fleming J; Li M; Kang Y; Zhang R; Li D
    PLoS One; 2015; 10(3):e0121082. PubMed ID: 25793983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
    Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
    BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance.
    Wang G; Chen J; Dai S; Zhang J; Gao Y; Yin L; Jiang K; Miao Y; Lu Z
    Apoptosis; 2024 Apr; 29(3-4):344-356. PubMed ID: 37848674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
    Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
    J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
    Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
    Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels.
    Kong B; Wu W; Valkovska N; Jäger C; Hong X; Nitsche U; Friess H; Esposito I; Erkan M; Kleeff J; Michalski CW
    Sci Rep; 2015 Feb; 5():8109. PubMed ID: 25657029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte nuclear factor 1 alpha influences pancreatic cancer growth and metastasis.
    Subramani R; Medel J; Flores K; Perry C; Galvez A; Sandoval M; Rivera S; Pedroza DA; Penner E; Chitti M; Lakshmanaswamy R
    Sci Rep; 2020 Nov; 10(1):20225. PubMed ID: 33214606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
    Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
    J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
    Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
    Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
    [No Abstract]   [Full Text] [Related]  

  • 17. HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties.
    Abel EV; Goto M; Magnuson B; Abraham S; Ramanathan N; Hotaling E; Alaniz AA; Kumar-Sinha C; Dziubinski ML; Urs S; Wang L; Shi J; Waghray M; Ljungman M; Crawford HC; Simeone DM
    Elife; 2018 Aug; 7():. PubMed ID: 30074477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
    Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HNF1A/CASC2 regulates pancreatic cancer cell proliferation through PTEN/Akt signaling.
    Yu Y; Liang S; Zhou Y; Li S; Li Y; Liao W
    J Cell Biochem; 2019 Mar; 120(3):2816-2827. PubMed ID: 28865121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
    Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
    J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.